Thyroid Feedback Quantile-based Index
| Thyroid Feedback Quantile-based Index | |
|---|---|
| Synonyms | TFQI |
| Reference range | –0.74 – +0.74 |
| Test of | Sensitivity of TSH-producing pituitary cells to thyroid hormones; also a marker for the set point of thyroid homeostasis |
The Thyroid Feedback Quantile-based Index (TFQI) is a calculated parameter for thyrotopic pituitary function. It was defined to be more robust to distorted data than Jostel's TSH index (JTI) and the thyrotroph thyroid hormone sensitivity index (TTSI).
How to determine the TFQI
The TFQI can be calculated with
from quantiles of FT4 and TSH concentration (as determined based on cumulative distribution functions).[1] Per definition the TFQI has a mean of 0 and a standard deviation of 0.37 in a reference population.[1] This explains the reference range of –0.74 to + 0.74.
Reference range
| Parameter | Lower limit | Upper limit | Unit |
| TTSI | –0.74 | +0.74 |
Clinical significance
Higher values of TFQI are associated with obesity, metabolic syndrome, impaired renal function, diabetes, and diabetes-related mortality.[1][2][3][4][5][6][7] TFQI results are also elevated in takotsubo syndrome,[8] potentially reflecting type 2 allostatic load in the situation of psychosocial stress. Reductions have been observed in subjects with schizophrenia after initiation of therapy with oxcarbazepine, potentially reflecting declining allostatic load[9].
See also
- Thyroid function tests
- Thyroid's secretory capacity
- Sum activity of peripheral deiodinases
- Jostel's TSH index
- Thyrotroph Thyroid Hormone Sensitivity Index
References
- ^ a b c Laclaustra, M; Moreno-Franco, B; Lou-Bonafonte, JM; Mateo-Gallego, R; Casasnovas, JA; Guallar-Castillon, P; Cenarro, A; Civeira, F (February 2019). "Impaired Sensitivity to Thyroid Hormones Is Associated With Diabetes and Metabolic Syndrome". Diabetes Care. 42 (2): 303–310. doi:10.2337/dc18-1410. PMID 30552134.
- ^ "Schilddrüsenhormonresistenz und Risiko für Diabetes und metabolisches Syndrom". Diabetologie und Stoffwechsel. 14 (2): 78. 16 April 2019. doi:10.1055/a-0758-5718. S2CID 243074371.
- ^ Paschou, Stavroula A.; Alexandrides, Theodoros (19 October 2019). "A year in type 2 diabetes mellitus: 2018 review based on the Endorama lecture". Hormones. 18 (4): 401–408. doi:10.1007/s42000-019-00139-z. PMID 31630372. S2CID 204786351.
- ^ Guan, Haixia (April 2019). "Mild Acquired Thyroid Hormone Resistance Is Associated with Diabetes-Related Morbidity and Mortality in the General Population". Clinical Thyroidology. 31 (4): 138–140. doi:10.1089/ct.2019;31.138-140. S2CID 145947179.
- ^ Lou-Bonafonte, José Manuel; Civeira, Fernando; Laclaustra, Martín (20 February 2020). "Quantifying Thyroid Hormone Resistance in Obesity". Obesity Surgery. 30 (6): 2411–2412. doi:10.1007/s11695-020-04491-7. PMID 32078724. S2CID 211217245.
- ^ "甲状腺素抵抗与糖尿病和代谢综合征有关？看TFQI怎么说". www.medinfo-sanofi.cn. Retrieved 14 April 2020.
- ^ Yang, S; Lai, S; Wang, Z; Liu, A; Wang, W; Guan, H (December 2021). "Thyroid Feedback Quantile-based Index correlates strongly to renal function in euthyroid individuals". Annals of Medicine. 53 (1): 1945–1955. doi:10.1080/07853890.2021.1993324. PMC 8567884. PMID 34726096.
- ^ Aweimer, A; El-Battrawy, I; Akin, I; Borggrefe, M; Mügge, A; Patsalis, PC; Urban, A; Kummer, M; Vasileva, S; Stachon, A; Hering, S; Dietrich, JW (12 November 2020). "Abnormal thyroid function is common in takotsubo syndrome and depends on two distinct mechanisms: results of a multicentre observational study". Journal of Internal Medicine. 289 (5): 675–687. doi:10.1111/joim.13189. PMID 33179374.
- ^ Zhai, D; Chen, J; Guo, B; Retnakaran, R; Gao, S; Zhang, X; Hao, W; Zhang, R; Zhao, Y; Wen, SW (1 December 2021). "Oxcarbazepine was associated with risks of newly developed hypothyroxinemia and impaired central set point of thyroid homeostasis in schizophrenia patients". British journal of clinical pharmacology. doi:10.1111/bcp.15163. PMID 34855997.